Lyell Immunopharma Announces Closing of Additional $50 Million Tranche of Equity Private Placement and Appointment of Smital Shah as Chief Financial and Business Officer

AI Briefing

• – Lyell Immunopharma closes $50M equity private placement, appoints Smital Shah as CFO.
• – Rondecabtagene autoleucel achieves clinical milestone in PiNACLE trial.
• – Smital Shah joins Lyell as Chief Financial and Business Officer.